ライフサイエンスコーパス: cycloplegic

1 Examinations included cycloplegic (1% cyclopentolate) autorefraction, and meas

2 Tropicamide (1%) is an effective cycloplegic agent in myopic children.

3 Although cycloplegic and corticosteroid therapy may resolve some

4 Cycloplegic and manifest refraction were performed on 44

5 on of children with < 1-D difference between cycloplegic and PlusOptix A09 refraction was 68.8 %, hig

6 orithm included antiglaucoma medications and cycloplegics as first-line methods; the second-line ther

7 quivalent differed between PlusOptix A09 and cycloplegic autorefraction (+0.54 [1.82] D vs +1.06 [2.0

8 leted a comprehensive examination, including cycloplegic autorefraction (cyclopentolate 1%; Canon RK-

9 Cycloplegic autorefraction (cyclopentolate 1%; Canon RK-

10 al meridians of the right eye as measured by cycloplegic autorefraction (n = 45 children).

11 09 refraction was positively correlated with cycloplegic autorefraction (r = 0.81, p < 0.001) with hi

12 difference between the spherical equivalent cycloplegic autorefraction 30 degrees in the nasal visua

13 difference between the spherical equivalent cycloplegic autorefraction 30 degrees in the nasal visua

14 trial is progression of myopia determined by cycloplegic autorefraction after inducement of cyclopleg

15 In addition to measures of myopia by cycloplegic autorefraction and AL by A-scan ultrasonogra

16 Eye examinations included cycloplegic autorefraction and ocular biometric measures

17 pal meridian in the right eye as measured by cycloplegic autorefraction at any visit after baseline u

18 r evaluations that included axial length and cycloplegic autorefraction at the beginning and after 1

19 , 6-11 years) with spherical equivalent (SE) cycloplegic autorefraction between -0.75 D and -4.50 D w

20 6 to 11 years with spherical equivalent (SE) cycloplegic autorefraction between -0.75 diopters (D) an

21 uivalent refraction of both eyes obtained by cycloplegic autorefraction between the baseline and 5-ye

22 Refractive error (cycloplegic autorefraction confirmed by retinoscopy), be

23 Children were followed up with cycloplegic autorefraction every 4 months over 2 years.

24 nd a comprehensive eye examination including cycloplegic autorefraction from 100 census tracts.

25 1 incident myopes (-0.75 D or more myopia on cycloplegic autorefraction in both meridians) and 587 em

26 ol-based studies assessing hyperopia through cycloplegic autorefraction or cycloplegic retinoscopy.

27 a onset in the right eye was the right eye's cycloplegic autorefraction spherical refractive error va

28 sOptix A09 refraction is closer to that with cycloplegic autorefraction than non-cycloplegic autorefr

29 The mean spherical equivalent measured by cycloplegic autorefraction was -2.38 +/- 0.81 D.

30 an (SD) difference between PlusOptix A09 and cycloplegic autorefraction was higher with hyperopia tha

31 tumbling-E charts in 3997 to 5949 children; cycloplegic autorefraction was performed and best correc

32 ridians -0.75 diopters [D] or more myopia by cycloplegic autorefraction) in the Collaborative Longitu

33 ory, colour vision, gross stereopsis and non-cycloplegic autorefraction) were conducted on 81% of a p

34 -0.75 D or more myopia in both meridians (by cycloplegic autorefraction).

35 corneal curvatures were measured annually by cycloplegic autorefraction, and axial length was measure

36 Cycloplegic autorefraction, conjunctival ultraviolet aut

37 cluding monocular VA testing, cover testing, cycloplegic autorefraction, fundus evaluation, and VA re

38 Using cycloplegic autorefraction, video-based phakometry, and

39 hat with cycloplegic autorefraction than non-cycloplegic autorefraction.

40 D) and emmetropic status were determined by cycloplegic autorefraction.

41 The refractive error was measured using cycloplegic autorefraction.

42 luded assessment of logMAR visual acuity and cycloplegic autorefraction.

43 visual field was measured annually by using cycloplegic autorefraction.

44 al coherence tomographer was used to measure cycloplegic ciliary muscle thicknesses at 1 mm (CMT1), 2

45 -up examination included refractometry under cycloplegic conditions.

46 l without correction, and retested with full cycloplegic correction when retest criteria were met.

47 Visual acuity was retested with full cycloplegic correction when retest criteria were met.

48 Cycloplegics, corticosteroids, and nonsteroidal anti-inf

49 To evaluate the cycloplegic effect of 1% tropicamide in myopic children

50 with the addition of topical steroids and/or cycloplegics in eyes that demonstrated anterior chamber

51 cover testing, best corrected visual acuity, cycloplegic objective refraction, slit lamp as well as f

52 ere compared by histology, laser micrometry, cycloplegic photorefractions, and partial coherence inte

53 The spherical equivalent value with non-cycloplegic PlusOptix A09 refraction is closer to that w

54 (best-corrected visual acuity, stereoacuity, cycloplegic refraction and funduscopy).

55 nt a comprehensive eye examination including cycloplegic refraction and sensorimotor testing within 6

56 Examinations included cycloplegic refraction by retinoscopy, keratometry measu

57 Longitudinal (0-7 years) cycloplegic refraction data were collected prospectively

58 ngen, Germany) after vision tests and before cycloplegic refraction tests.

59 For the right eye, mean cycloplegic refraction was +15.09 diopters (D) (range 9.

60 Cycloplegic refraction was measured at baseline and 10 y

61 age who were undergoing general anesthesia, cycloplegic refraction was measured using streak retinos

62 Cycloplegic refraction was used to identify hyperopia (>

63 Measurements of peripheral refraction and cycloplegic refraction were obtained at three visits ove

64 signed to overminus spectacles (-2.50 D over cycloplegic refraction) or observation (non-overminus sp

65 vided as spectacles (prescription based on a cycloplegic refraction) that were worn for the first tim

66 Cycloplegic refraction, axial length, accommodation ampl

67 on, corrected distance visual acuity (CDVA), cycloplegic refraction, slitlamp biomicroscopy, and kera

68 d for spectacle correction was determined by cycloplegic refraction.

69 xamination, including dilated fundoscopy and cycloplegic refraction.

70 al acuity testing, stereoacuity testing, and cycloplegic refraction.

71 cy was evaluated by comparison to results of cycloplegic refraction.

72 severe ROP should be monitored with periodic cycloplegic refractions and provided with early optical

73 Cycloplegic refractions culled from medical records were

74 Manifest refractions, cycloplegic refractions, uncorrected and best-corrected

75 ith keratometry, A-scan ultrasonography, and cycloplegic refractions.

76 The results were compared to the subjects' cycloplegic refractions.

77 Cycloplegic refractive error and ocular components measu

78 Cycloplegic refractive error was measured in 75 Labrador

79 Cycloplegic refractive error was measured with an autore

80 Accommodative response and cycloplegic refractive error were measured by autorefrac

81 After 11 days of treatment, cycloplegic refractive state and axial component dimensi

82 th treatment randomized by infant, underwent cycloplegic retinoscopic refraction at a mean age of 2(1

83 equivalent refractive error was measured by cycloplegic retinoscopy (cyclopentolate 1%).

84 Refractive development was assessed by cycloplegic retinoscopy and A-scan ultrasonography.

85 vision screening referral criteria underwent cycloplegic retinoscopy and ophthalmoscopy by the on-sit

86 Spot (0.806) and excellent agreement between cycloplegic retinoscopy and Plusoptix (0.898).

87 equivalents indicated good agreement between cycloplegic retinoscopy and Spot (0.806) and excellent a

88 001 for both) but was in good agreement with cycloplegic retinoscopy for cylinder power and axis.

89 significantly more myopic measurements than cycloplegic retinoscopy for the sphere and spherical equ

90 tinoscopy under anesthesia was within 1 D of cycloplegic retinoscopy in 25 subjects (61%) for the sph

91 nce between retinoscopy under anesthesia and cycloplegic retinoscopy in children.

92 The photorefractors correlated with cycloplegic retinoscopy refractive findings for sphere a

93 nce between retinoscopy under anesthesia and cycloplegic retinoscopy was -0.98 diopters (D) (95% limi

94 ination included visual acuity (VA) testing, cycloplegic retinoscopy with subjective refinement if in

95 Cycloplegic retinoscopy, A-scan ultrasonography, slit la

96 Compared with cycloplegic retinoscopy, both devices underestimated hyp

97 velopment was assessed every 2 to 3 weeks by cycloplegic retinoscopy, keratometry and corneal videoto

98 effects of continuous light were assessed by cycloplegic retinoscopy, keratometry, and A-scan ultraso

99 shold visual acuity (VA), cover testing, and cycloplegic retinoscopy, performed by VIP-certified opto

100 were invited to follow-up a month later for cycloplegic retinoscopy, repeat noncycloplegic videorefr

101 eropia through cycloplegic autorefraction or cycloplegic retinoscopy.

102 tance visual acuity (VA), cover testing, and cycloplegic retinoscopy.

103 ant in some as compared to the tone found in cycloplegic retinoscopy.

104 Refractive status was confirmed with cycloplegic retinoscopy.

105 eorefraction with repeat videorefraction and cycloplegic retinoscopy.

106 for refractive errors, measured by standard cycloplegic retinoscopy.

107 screening procedure, simpler to perform than cycloplegic screening, succeeded in detecting a large pr

108 ng a high (versus low) risk of myopia with a cycloplegic sphere cutoff of +0.75 D or less (versus mor

109 Cases were defined as 1. Myopia onset (cycloplegic spherical equivalent </= -0.5 diopter in non

110 ewed at 26, 32 and 36 months, and changes in cycloplegic spherical equivalent (SE), axial length (AL)

111 An autorefractor was used to determine cycloplegic spherical equivalent refractive error (SPHEQ

112 dicted with moderate accuracy using the mean cycloplegic, spherical refractive error in the third gra

113 conjunction with topical corticosteroid and cycloplegic therapy.